Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Syros Pharmaceuticals
Biotech
Syros flunks phase 3 blood cancer trial, triggering loan default
Syros saw a 23.8% complete response rate in people who received the combination, compared to 18.8% in patients who got placebo on top of azacitidine.
Nick Paul Taylor
Nov 13, 2024 10:00am
Syros’ stock up after early AML data share
Dec 6, 2023 10:45am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
After 2 partners walk away, Syros cuts 35% of workforce
Oct 2, 2023 11:06am
Incyte drops Syros blood cancer partnership, following Pfizer
Aug 14, 2023 10:45am
Pfizer drops sickle cell collab with Syros inherited from GBT
Jul 24, 2023 10:23am
